Semiconductors Are Getting Repriced. Healthcare Is Getting Rewarded.

The Nasdaq shed 2.21% on Tuesday, per CNBC, and the names doing the most damage were chip and AI infrastructure stocks. Meanwhile, the ACCE Biotech Catalysts index gained 2.25% this week. That divergence is not noise. It is a sector rotation worth understanding before it goes further.

The macro backdrop shifted meaningfully this month. Following the June 17 FOMC meeting, Chair Kevin Warsh removed language pointing to future rate cuts and signaled a hawkish bias, per the Federal Reserve. Markets are now pricing approximately a 68% probability of at least one 25-basis-point rate hike by September, up from roughly 29% the prior week, according to Trading Economics. The 10-year Treasury yield is holding around 4.5%.

That matters for healthcare in a specific way. Large-cap biopharma and specialty pharma are not pure duration plays, unlike unprofitable growth names. When the rate-hike probability jumps 39 percentage points in a week, the names that get hit hardest are those whose valuations depend on discounting cash flows far into the future at low rates. Healthcare leaders right now are generating real earnings, real free cash flow, and, in several cases, real dividends. That profile holds up better in a hawkish repricing than a basket of pre-revenue AI infrastructure names trading at triple-digit forward multiples.

The global chip selloff that drove Tuesday’s session, sparked by a steep drop in South Korea’s KOSPI per CNBC, accelerated this dynamic. Investors rotating out of semiconductors and AI-adjacent names need somewhere to put capital. Defensive growth with visible earnings is the natural landing spot. Healthcare, particularly the large-cap end, fits that description.

The sector is not uniformly cheap. But the spread between its leaders and laggards has widened to a point where the composition of your healthcare exposure matters as much as whether you have any.

Novo Nordisk (NVO) is the most interesting setup in the data. Revenue grew 24.0% year-over-year, and earnings grew 67.1%, yet the stock is down 33.0% over the past year. The ACCE score sits at 76/100, with Quality at 96 and Value at 95, which is a rare combination. The FCF yield is 15.2%, and the forward P/E is 13.6x. The market is pricing in a GLP-1 competitive threat that is real but may be more than fully reflected at these levels. The counterargument: Eli Lilly is a formidable competitor, pipeline execution risk is genuine, and the stock has been a value trap for twelve months. Watch for any clinical data that shifts the competitive read on tirzepatide versus semaglutide in obesity outcomes.

Vertex Pharmaceuticals (VRTX) is the quality anchor. Net margin of 35.5%, ROE of 24.2%, Quality score of 91/100, and earnings grew 61.4% year-over-year. The forward P/E of 24.6x is not cheap, but for a franchise with near-monopoly positioning in cystic fibrosis and a pipeline expanding into pain and kidney disease, it is not obviously expensive either. The risk is pipeline concentration: if any late-stage program stumbles, the multiple compresses quickly.

Regeneron (REGN) offers a different profile: a 13.6x forward P/E, a FCF yield of 6.4%, and a net margin of 29.6%. Revenue grew 19.0% year-over-year. The ACCE Value score is 76. The drag is Dupixent’s biosimilar exposure timeline and the year-over-year earnings dip of 7.2%, which keeps momentum subdued (Momentum score: 39).

Coloplast (COLO-B) is the clearest laggard. Down 42.9% over the past year, it missed its most recent quarter by 1.0%, and Morgan Stanley cut its target by 17% this week. Revenue grew only 2.2% year-over-year. The Momentum score is 17/100. The dividend yield of 6.1% looks attractive in isolation, but a high yield on a declining stock is often a symptom, not a solution. The ACCE score is 50/100.

BioMarin (BMRN) sits in the middle: a forward P/E of 11.2x and FCF yield of 6.9% suggest value, but earnings fell 43.1% year-over-year, and the Growth score is 19/100. It is cheap for a reason, and the reason is not yet resolved.

The consensus read on healthcare right now is “defensive rotation into quality.” That is probably in the right direction, but it creates its own risk. When a sector becomes the obvious safe harbor, positioning gets crowded, and the valuation premium that made it attractive compresses. NVO, at a 76 ACCE score and 15.2% FCF yield, looks genuinely undervalued, but it has looked that way for most of the past year while the stock has continued lower. The contrarian question is not whether the fundamentals of healthcare are good. They are. The question is whether the rotation trade is already priced in after this week’s outperformance, and whether a surprise Fed pivot back toward cuts would send capital back into the growth names that just sold off. If the 68% probability of a September hike (per Trading Economics) reverses on softer data, the defensives-into-healthcare trade unwinds quickly.

The more durable case for healthcare is not the rotation. It is the earnings quality. Names like Vertex and Regeneron are generating cash now, not in 2028. That is a different argument than “chips are down, so buy pharma,” and it holds regardless of what the Fed does next.

Micron Technology reports after the bell on Wednesday, per CNBC. The result will not directly move healthcare, but it will set the tone for whether the semiconductor selloff deepens or stabilizes. A weak Micron print that extends the chip rout for another session likely pushes more capital toward the defensive growth trade, benefiting large-cap biopharma names. A stabilizing beat for chips could reverse some of this week’s rotation. Watch the 10-year yield alongside it: if it holds above 4.5% while chips recover, healthcare’s relative appeal narrows. If yields push higher amid renewed fears of rate hikes, the quality-and-cash-flow argument for names like VRTX and REGN gets stronger, not weaker.